Investors reassess GLP-1 pill market amid Novo Nordisk's Wegovy launch

Early performance of Novo Nordisk's Wegovy pill is prompting investors to reconsider Eli Lilly & Co.'s previously assumed dominance in the GLP-1 pill market.

4 May, 18:04 — 4 May, 18:04

Post Share

Sources

Showing 1 of 1 sources

cnbcMostly Factual119d ago

Novo Nordisk’s Wegovy pill head start forces investors to rethink Eli Lilly's GLP-1 dominance

Early signs from the launch of Novo Nordisk's Wegovy pill and Eli Lilly & Co.'s Foundayo are making investors rethink the opportunity for GLP-1 pills.

Read full article →

Investors reassess GLP-1 pill market amid Novo Nordisk's Wegovy launch

Sources

Novo Nordisk’s Wegovy pill head start forces investors to rethink Eli Lilly's GLP-1 dominance

Related Stories

Lionel Richie Hospitalized in ICU Following St. Louis Concert

Anna Hazare admitted to Mumbai hospital's ICU with acute dehydration, kidney issue

Ebola Outbreak in Democratic Republic of Congo Surpasses 6,000 Cases

England Pharmacies to Offer Free Quick Cholesterol Screening Tests